TCIM
ACHN

TIAA CREF Investment Management’s Achillion Pharmaceuticals ACHN Stock Holding History

TIAA CREF Investment Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$2.29M Buy
773,231
+516,702
+201% +$1.27M ﹤0.01% 1933
2018
Q4 		$408K Sell
256,529
-27,161
-10% -$76.8K ﹤0.01% 2653
2018
Q3 		$1.04M Sell
283,690
-338,170
-54% -$1.01M ﹤0.01% 2402
2018
Q2 		$1.76M Sell
621,860
-174,529
-22% -$594K ﹤0.01% 2236
2018
Q1 		$2.96M Buy
796,389
+432,818
+119% +$1.42M ﹤0.01% 1882
2017
Q4 		$1.05M Buy
363,571
+42,358
+13% +$154K ﹤0.01% 2442
2017
Q3 		$1.44M Sell
321,213
-107,720
-25% -$478K ﹤0.01% 2336
2017
Q2 		$1.97M Buy
428,933
+21,183
+5% +$85.1K ﹤0.01% 2187
2017
Q1 		$1.72M Buy
407,750
+10,558
+3% +$43.8K ﹤0.01% 2224
2016
Q4 		$1.64M Sell
397,192
-102,636
-21% -$546K ﹤0.01% 2288
2016
Q3 		$4.05K Buy
499,828
+17,316
+4% +$147K ﹤0.01% 1744
2016
Q2 		$3.76M Sell
482,512
-42,479
-8% -$364K ﹤0.01% 1742
2016
Q1 		$4.05M Sell
524,991
-54,928
-9% -$402K ﹤0.01% 1643
2015
Q4 		$6.26M Buy
579,919
+101,814
+21% +$926K ﹤0.01% 1388
2015
Q3 		$3.3M Sell
478,105
-43,323
-8% -$353K ﹤0.01% 1837
2015
Q2 		$4.62M Buy
521,428
+41,421
+9% +$392K ﹤0.01% 1741
2015
Q1 		$4.73M Buy
480,007
+48,226
+11% +$602K ﹤0.01% 1678
2014
Q4 		$5.29M Sell
431,781
-20,052
-4% -$245K ﹤0.01% 1590
2014
Q3 		$4.51M Buy
451,833
+8,338
+2% +$77.4K ﹤0.01% 1682
2014
Q2 		$3.36M Buy
443,495
+37,541
+9% +$150K ﹤0.01% 1963
2014
Q1 		$1.34M Sell
405,954
-9,530
-2% -$33.4K ﹤0.01% 2474
2013
Q4 		$1.38M Buy
415,484
+29,500
+8% +$85.6K ﹤0.01% 2479
2013
Q3 		$1.17M Sell
385,984
-15,519
-4% -$106K ﹤0.01% 2530
2013
Q2 		$3.28M Buy
+401,503
New +$3.07M ﹤0.01% 1827

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TIAA CREF Investment Management's ACHN Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Achillion Pharmaceuticals (ACHN) stake by 201% in Q1 2019, buying an estimated $1.27M and bringing the position to 773,231 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1933.

TIAA CREF Investment Management first reported a position in ACHN in Q2 2013 and has held it in 24 quarters since. The position peaked at $6.26M in Q4 2015. 110 funds tracked by Wall St. Rank hold ACHN as of Q1 2019.

  • TIAA CREF Investment Management held 773,231 shares of Achillion Pharmaceuticals worth $2.29M as of Q1 2019.
  • TIAA CREF Investment Management bought 516,702 Achillion Pharmaceuticals shares in Q1 2019, an estimated $1.27M.
  • Achillion Pharmaceuticals made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1933 holding.
  • TIAA CREF Investment Management first reported a position in Achillion Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Achillion Pharmaceuticals position peaked at $6.26M in Q4 2015.
  • 110 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.